These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30782092)

  • 1. Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma.
    Dasanu CA
    J Oncol Pharm Pract; 2019 Dec; 25(8):2052-2055. PubMed ID: 30782092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab-associated Stevens-Johnson syndrome in a patient with lung cancer.
    Gracia-Cazaña T; Padgett E; Calderero V; Oncins R
    Dermatol Online J; 2021 Mar; 27(3):. PubMed ID: 33865285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.
    Zhang J; Zhang P; Xu QY; Zhu YT; Chen W; Ji C
    Australas J Dermatol; 2022 Feb; 63(1):e71-e74. PubMed ID: 34463968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case Series of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis With Nivolumab and Nivolumab/ Ipilimumab Combination Therapy in Metastatic Melanoma.
    Lee O; Masood M; Nutan F
    J Drugs Dermatol; 2022 May; 21(5):529-530. PubMed ID: 35533039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy.
    Hwang A; Iskandar A; Dasanu CA
    J Oncol Pharm Pract; 2019 Sep; 25(6):1520-1522. PubMed ID: 30086678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal Lichen Planus Mimicking Mucosal Lesions in Stevens-Johnson Syndrome after Nivolumab Therapy.
    Miyagawa F; Nakajima A; Ohyama SI; Aoki Y; Nishikawa M; Nakamura Y; Hashimoto T; Asada H
    Acta Derm Venereol; 2019 Jun; 99(7):687-688. PubMed ID: 30938822
    [No Abstract]   [Full Text] [Related]  

  • 7. Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1®) after nivolumab discontinuation.
    Komatsu-Fujii T; Ogawa M; Nonoyama S; Fukumoto T; Tanabe H
    Eur J Dermatol; 2021 Feb; 31(1):98-99. PubMed ID: 33586655
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.
    Choi B; McBride A; Scott AJ
    Am J Health Syst Pharm; 2019 Oct; 76(21):1749-1752. PubMed ID: 31612928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab.
    Rouyer L; Bursztejn AC; Charbit L; Schmutz JL; Moawad S
    Eur J Dermatol; 2018 Jun; 28(3):380-381. PubMed ID: 29952288
    [No Abstract]   [Full Text] [Related]  

  • 10. Multiple Cranial Neuropathies From Nivolumab in a Patient With Metastatic Hepatocellular Carcinoma.
    Siegel CH; Finn RS; Ho MG
    Mayo Clin Proc; 2018 Apr; 93(4):540-541. PubMed ID: 29622100
    [No Abstract]   [Full Text] [Related]  

  • 11. Stevens-Johnson syndrome during nivolumab treatment of NSCLC.
    Salati M; Pifferi M; Baldessari C; Bertolini F; Tomasello C; Cascinu S; Barbieri F
    Ann Oncol; 2018 Jan; 29(1):283-284. PubMed ID: 29045532
    [No Abstract]   [Full Text] [Related]  

  • 12. Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome.
    Shah KM; Rancour EA; Al-Omari A; Rahnama-Moghadam S
    Dermatol Online J; 2018 Jun; 24(6):. PubMed ID: 30142712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angioedema late in the course of adjuvant nivolumab therapy for melanoma.
    Ratra A; Dasanu CA
    J Oncol Pharm Pract; 2020 Jun; 26(4):1019-1021. PubMed ID: 31635547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab for the treatment of hepatocellular carcinoma.
    Finkelmeier F; Waidmann O; Trojan J
    Expert Rev Anticancer Ther; 2018 Dec; 18(12):1169-1175. PubMed ID: 30304963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
    Coleman E; Ko C; Dai F; Tomayko MM; Kluger H; Leventhal JS
    J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxic epidermal necrolysis accompanied by several immune-related adverse events developed after discontinuation of nivolumab.
    Watanabe Y; Yamaguchi Y; Takamura N; Takahashi Y; Aihara M
    Eur J Cancer; 2020 May; 131():1-4. PubMed ID: 32248069
    [No Abstract]   [Full Text] [Related]  

  • 17. Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review.
    Maloney NJ; Ravi V; Cheng K; Bach DQ; Worswick S
    Int J Dermatol; 2020 Jun; 59(6):e183-e188. PubMed ID: 32052409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastric necrosis after nivolumab therapy in a patient with advanced hepatocellular carcinoma.
    Hsu WF; Lin YC; Chiang IP; Peng CY
    Dig Liver Dis; 2021 Nov; 53(11):1506-1507. PubMed ID: 32928671
    [No Abstract]   [Full Text] [Related]  

  • 19. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
    Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe bullous skin eruptions on checkpoint inhibitor therapy - in most cases severe bullous lichenoid drug eruptions.
    Reschke R; Mockenhaupt M; Simon JC; Ziemer M
    J Dtsch Dermatol Ges; 2019 Sep; 17(9):942-948. PubMed ID: 31210413
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.